Recently a resolution to revise the Pediatric Medicines Regulation (PMR) was passed by the European Parliament. According the pediatric investigation plan (PIP), the pharmaceutical industry are obligated to test all new medicines in children and adults and can obtain market exclusivity in return. However, they can obtain an exemption or waiver, such as when the company is developing a drug for adult cancer which does not exist in children. This can be of great disadvantage as the drug could be used to treat other forms of childhood cancer. The resolution asks for a framework in which the pharmaceutical industry cannot sidestep this legal obligation abut also get additional incentives to carry out trials in children.
A joint statement International Society of Pediatric Oncology (SIOP) and Childhood Cancer International (CCI) published in The Lancet Oncology, lay down ways to galvanize the international oncology community to achieve sustained improvements in access to medicines for children with cancer, regardless of disease or geography.” They also make recommendations to improve global access to medicines for cancer. These include availability accessibility, acceptability affordability and quality all of which is explained in detail.